NCT04818372 2021-11-12Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and LymphomaKeymed Biosciences Co.LtdPhase 1 Unknown87 enrolled
NCT01307592 2014-01-10Gemcitabine Hydrochloride, Rituximab, Oxaliplatin, and Lenalidomide in Treating Patients With Relapsed or Refractory, Aggressive Non-Hodgkin LymphomaNational Cancer Institute (NCI)Phase 2 Unknown70 enrolled